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ABSTRACT
BACKGROUNDANDPURPOSE: The serial imaging changes describing the growth of glioblastomas from small to large tumors are seldom
reported. Our aim was to classify the imaging patterns of early-stage glioblastomas and to define the order of appearance of different
imaging patterns that occur during the growth of small glioblastomas.
MATERIALS AND METHODS: Medical records and preoperative MR imaging studies of patients diagnosed with glioblastoma between
2006 and 2013 were reviewed. Patients were included if their MR imaging studies showed early-stage glioblastomas, defined as small MR
imaging lesions detected early in the course of the disease, demonstrating abnormal signal intensity but the absence of classic imaging
findings of glioblastoma. Each lesion was reviewed by 2 neuroradiologists independently for location, signal intensity, involvement of GM
and/or WM, and contrast-enhancement pattern on MR imaging.
RESULTS: Twenty-six patients with 31 preoperativeMR imaging studiesmet the inclusion criteria. Early-stage glioblastomaswere classified
into 3 types and were all hyperintense on FLAIR/T2-weighted images. Type I lesions predominantly involved cortical GM (n 3). Type II
(n  12) and III (n  16) lesions involved both cortical GM and subcortical WM. Focal contrast enhancement was present only in type III
lesions at the gray-white junction. Interobserver agreement was excellent ( 0.95; P .001) for lesion-type classification. Transforma-
tions of lesions from type I to type II and type II to type III were observed on follow-upMR imaging studies. The early-stage glioblastomas
of 16 patients were pathologically confirmed after imaging progression to classic glioblastoma.
CONCLUSIONS: Cortical lesions may be the earliest MR imaging–detectable abnormality in some human glioblastomas. These cortical
tumors may progress to involve WM.
ABBREVIATIONS: GB glioblastoma; IDH1 isocitrate dehydrogenase 1
Glioblastoma (GB) is the most common primary malignantbrain tumor. It typically appears as a large mass with necro-
sis, prominent edema,mass effect, and strong heterogeneous con-
trast enhancement when diagnosed. MR imaging, a noninvasive
diagnostic tool with excellent tissue contrast, has the potential to
detect small GBs. However, it is uncommon to detect small GBs
clinically, probably due to nonspecific or absent symptoms. The
serial imaging changes depicting the growth of GBs from small to
large tumors are seldom reported.
Some reports described small MR imaging lesions that subse-
quently progressed to GBs.1-11 These are often described as ill-
defined, FLAIR or T2-weighted hyperintensities without discern-
able mass effect that typically involve both the cortex and
subcortical WM, but occasionally appear as only cortical le-
sions.2,4,8 Contrast enhancement is not a consistent feature and
tends to be focal and nodular when present.6-8 The commonly
affected brain areas include frontal (n  4),2,3,6,8 parietal (n 
2),7,10 occipital (n 1),11 temporal (n 5),2,3,6,7,11 hippocampal
(n 3),1,2,9 and insular (n 1)9 regions. Because these MR im-
aging lesions were detected early in the course of the disease, they
were frequently referred to as early-stage GBs.3,5-8,11
We have noticed different imaging patterns in early-stageGBs.
An imaging classification for early-stageGB, however, is not avail-
able becausemost previous studies included only a few such cases.
It is important for radiologists to be familiar with early imaging
findings and growth patterns of GBs because familiarity may help
diagnose small tumors that are symptomatic or incidentally
found. Early diagnosis of GBmay lead to a higher extent of tumor
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resection, which has been demonstrated to correlate with patient
survival.12 In this study, we aimed to classify the imaging patterns of
early-stageGBs and to the define the order of appearance of different
imaging patterns that occur during the growth of these tumors.
MATERIALS AND METHODS
This retrospective longitudinal observational cohort study was
performed in 2 medical centers (Chang GungMemorial Hospital
at Linkou and University of North Carolina Medical Center at
Chapel Hill) after institutional review board approval with a
waiver of the informed consent requirement. The study was per-
formed in compliance with the Health Insurance Portability and
Accountability Act.
A search of the hospital data base was first performed at both
institutions for patients diagnosed with glioblastoma between
2006 and 2013. By reviewing their medical records and all available
preoperative MR imaging studies, we excluded patients with GBs
transformed from histology-proved low-grade gliomas, gliomatosis
cerebri, ahistoryofcranial irradiationbefore thediagnosisofGB,and
poor image quality. Patients with preoperative MR imaging studies
demonstrating early-stage glioblastomas were included.
Early-stage GBs were defined as small MR imaging lesions de-
tected early in the course of the disease, demonstrating abnormal
signal intensity on T2-weighted, FLAIR, and/or postcontrast T1-
weighted images but with an absence of the imaging findings of
classic GB, such as tumors with necrosis, hemorrhage, prominent
edema, and heterogeneous contrast enhancement. These lesions
were all subsequently proved by histopathology to be GBs. They
did or did not develop into classicGBs onMR imaging, depending
on the timing of the operation and the frequency of follow-up
studies. At each institution, histologic sections were reviewed by
neuropathologists with 15 years of experience, and diagnosis
was made according to World Health Organization criteria.
Besides MR imaging findings, clinical information collected
from each patient included age, sex, and tumor isocitrate dehydro-
genase (IDH1) gene mutation status determined by immunohis-
tochemistry study, if available.
Imaging Protocols
Because the MR imaging studies were performed at 2 medical
centers with 1.5T or 3T clinicalMR imaging scanners (Magnetom
Espree, Avanto, or Tim Trio; Siemens, Erlangen, Germany; Op-
tima MR450w with GEM Suite or Discovery MR750; GE Health-
care, Milwaukee, Wisconsin; or Intera; Philips, Best, the Nether-
lands), their imaging parameters were not consistent.
The imaging protocol for 1.5TMR imaging scanners typically
included transverse T1WI (TR/TE, 449/12 ms; section thickness,
5 mm; gap, 1 mm; matrix, 256 512; and FOV, 210 178 mm),
transverse FSE T2WI (TR/TE, 4000/90 ms; section thickness, 5
mm; gap, 1 mm; echo-train length, 17; matrix, 304  512; and
FOV, 210  178 mm), transverse FLAIR (TR/TE/TI, 9788/90/
2300 ms; section thickness, 5 mm; gap, 1 mm; matrix, 256 512;
and FOV, 210  178 mm), and postcontrast T1WI (TR/TE,
420/11 ms; section thickness, 5 mm; gap, 1 mm; matrix, 256 
512; and FOV, 210 178mm). For 3T scanners, the typical pulse
sequences included transverse T1WI (TR/TE, 250/2.46 ms; sec-
tion thickness, 4 mm; gap, 1 mm; matrix, 256  256; and FOV,
220 220 mm), transverse FSE T2WI (TR/TE, 4000/90 ms; sec-
tion thickness, 4 mm; gap, 1; flip angle, 120°; echo-train length,
17; matrix, 512  358; and FOV, 220  220 mm), transverse
FLAIR (TR/TE/TI, 8200/85/2500 ms; section thickness, 4 mm;
gap, 1 mm; matrix, 320  256; and FOV, 220  220 mm), and
postcontrast 3D MPRAGE (TR/TE/TI, 2530/4.03/1100 ms; sec-
tion thickness, 1 mm; matrix, 256  256; and FOV, 256  224
mm). A standard dose of 0.1 mmol of gadodiamide (Omniscan;
GE Healthcare, Piscataway, New Jersey) or gadopentetate dime-
glumine (Magnevist; Bayer HealthCare Pharmaceuticals, Wayne,
New Jersey) per kilogram of body weight was administered intra-
venously for postcontrast T1WI or MPRAGE.
Image Analysis
All available preoperative MR imaging studies for each patient
with early-stage GB were reviewed. Two neuroradiologists
(C.H.T. and M.C.) with 12 and 26 years of experience, respec-
tively, independently evaluated all lesions for their size, location,
involvement of GM and/or WM, MR imaging signal intensity,
and contrast-enhancement pattern. Among the imaging features
reviewed, involvement of GMand/orWMand contrast-enhance-
ment patterns were used for lesion-type classification. Interob-
server differences in lesion type classification were resolved by
consensus.
The size of FLAIR/T2-weighted and contrast-enhancing le-
sions was measured by using a bidimensional method. For each
lesion, the largest and perpendicular diameters weremeasured on
a single axial image demonstrating the largest cross-sectional area
if the diameters were1 cm.Morphologic changes, such as lesion
enlargement, new contrast enhancement, or transformation to a
classic GB, were recorded when follow-up MR imaging studies
were available.
Statistical Analysis
The level of interobserver agreement for lesion-type classification
was determined by calculating the  coefficient. SPSS for Win-
dows, Version 20.0 (IBM, Armonk, New York), was used to per-
form the statistical analyses, and P values .05 were considered
statistically significant.
RESULTS
Between 2006 and 2013, 282 patients were diagnosed with GBs.
Among these, 46were secondaryGBs and 9were gliomatosis cere-
bri and therefore were excluded. In the remaining 227 patients, 26
patients (18 from Chang GungMemorial Hospital at Linkou and
8 from University of North Carolina Medical Center at Chapel
Hill) with 31MR imaging studiesmet the inclusion criteria. None
of these 26 patients had a history of cranial irradiation before the
diagnosis of GB or poor image quality. MR imaging findings of
early-stage GBs were classified into 3 types on the basis of GM
and/or WM involvement and patterns of contrast enhancement.
The 2 neuroradiologists agreed on lesion-type classification in 30
of 31MR imaging studies, with excellent interobserver agreement
(  0.95; P  .001). Tables 1, 2, and 3 summarize the clinical
characteristics of patients who presented with type I, II, and III
lesions, respectively.
Type I lesions were those that on the first available study, pre-
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dominantly involved GM (ie, the cerebral cortex). They appeared
as T2-weighted or FLAIR hyperintensities without contrast en-
hancement. Three patients had type I lesions (Fig 1). Type II
lesions were T2-weighted or FLAIR hyperintensities involving
the cortex and subcortical WMwithout contrast enhancement.
Twelve patients, including one who progressed from a type I
lesion, had type II lesions (Fig 2). Type III lesions were hyper-
intense on T2-weighted and FLAIR images, involved both the
cortex and subcortical WM, and demonstrated small focal ar-
eas of contrast enhancement at the GM-WM junction. The
diameter of enhancing focus was about 1 cm in all. Sixteen
patients, including 4 who progressed from type II, had type III
lesions (Fig 3).
Figure 4 summarizes the morphologic changes of the early-
stage GBs in 26 patients as observed in follow-up MR imaging
studies. One type I lesion transformed to a type II, and 4 type II
lesions transformed to type III. Reverse-order transformation (ie,
transformation from a type III lesion to types II and I or from type
II to I) was not observed.
Two type II and 8 type III lesions underwent an early operation
Table 1: Clinical characteristics of patients who presented with type I lesionsa
Patient
Sex/Age
(yr) Symptoms Lesion Location
Lesion Size
(cm)
Durationb (mo)
IDH1
Mutation
Type
II
Type
III
Classic
GB
1 M/55 Focal seizure Right insula and temporal cortex 5 6 NA 11 
2 M/57 Focal seizure Left parietal cortex 2.2 NA NA 7 
3 M/60 Focal seizure Right insula and frontal operculum 3 NA NA 8 
Note:—NA indicates not available;, positive;, negative.
a The lesions refer to the FLAIR/T2-weighted hyperintensities predominantly involving cortical GM. Their perpendicular diameters were1 cm and therefore not measured.
b The duration is the time interval between the first and follow-up MR imaging studies showing type II lesions, type III lesions, or classic GB, respectively. NA indicates that the
particular lesion type was not detected during the course of follow-up.
Table 2: Clinical characteristics of patients who presented with type II lesionsa
Patient
Sex/Age
(yr) Symptoms Lesion Location
Lesion Size
(cm)
Durationb (mo)
IDH1
Mutation
Type
III
Classic
GB
1 M/48 LOC Left temporal 2 1.2 NA 12 
2 F/40 Syncope Right insula and frontal
operculum
4 2.5 NA 11 NS
3 F/32 Speech Left parietal 2.5 2 NA 4 
4 M/33 Headache, LOC Right insular 3.1 2.5 NA 4 NS
5 F/58 Gait disturbance, memory
impairment
Right medial frontal 4 3 10 13 NS
6 M/48 Focal seizure Right parietal 3.5 2.5 8 10 
7 F/78 Headache Right temporal 2.5 1 NA 2 
8 M/41 Focal seizure Left temporal 3 2 1 1.5 
9 M/40 Generalized seizure Left parietal 3 2.8 NA NA NS
10 M/71 Visual TIA Right occipital 3 3 2 NA NS
11 M/27 Focal seizure Left frontal 2.2 2.8 NA NA 
Note:—LOC indicates loss of conscious; NA, not available; NS, not studied;, positive;, negative.
a The lesions refer to the FLAIR/T2-weighted hyperintensities involving both cortical GM and subcortical WM.
b The duration is the time interval between the first and follow-up MR imaging studies showing a type III lesion or classic GB. NA indicates that the particular lesion type was
not detected during follow-up. The type II lesions of patients 9 and 11 were resected before they transformed to type III lesions or classic GB.
Table 3: Clinical characteristics of patients who presented with type III lesionsa
Patient
Sex/Age
(yr) Symptoms
Lesion
Location
Lesion Size
(cm)
Durationb (mo)
to Classic GB
IDH1
Mutation
1 F/95 Facial palsy Right frontal 3 1.5 3 NS
2 M/48 Generalized seizure Right frontal 4 2 NA 
3 M/69 Focal seizure Right parietal 2.5 1.2 3 
4 F/59 Slurred speech Left insular 3 1.3 NA NS
5 F/55 Hand numbness Right parietal 2.1 1.3 NA 
6 F/69 Leg weakness Right frontal 3 1.2 NA NS
7 F/35 Leg numbness Left frontal 2.5 1.3 1 
8 M/65 Generalized seizure Left parietal 2.6 2.6 NA NS
9 M/45 Generalized seizure Left temporal 3 3 1 NS
10 M/58 Generalized seizure Left frontal 1.5 1 NA NS
11 M/43 Generalized seizure Left frontal 3 1.8 NA NS
12 M/62 Generalized seizure Left temporal 2.4 2.3 6 
Note:—NA indicates not available; NS, not studied;, negative.
a The lesions refer to FLAIR/T2-weighted hyperintensities involving the cortex and subcortical WM, with focal contrast enhancement at the GM-WM junction. The size of
contrast-enhancing foci is not shown because they are about1 cm.
b The duration is the time interval between the first and follow-up MR imaging studies showing classic GB. NA indicates that type III lesions were resected before progressing
to classic GB.
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and were confirmed to be GBs. The early-stage GBs of 16 patients
were surgically resected after imaging progression to classic GB
was documented. IDH1 mutation status was available in 14
GBs, with 3 being positive for this mutation. The IDH1 muta-
tion rate was 21.4% (3 of 14).
DISCUSSION
In this study, we propose anMR imaging–based classification for
early-stage GBs. Lesions were classified into 3 types on the basis of
the involvement of GM and/orWMand their patterns of contrast
enhancement. The 3 types of MR imaging lesions may represent
sequential stages of human GB growth. To the best of our knowl-
edge, an MR imaging–based classification for early-stage GBs
does not exist.
Among the 3 types of lesions, type I was the earliest, followed
by type II, and then type III, according to the morphologic
changes observed on follow-upMR imaging studies. The order of
appearance suggests that someGBs start as T2-weighted or FLAIR
hyperintense lesions in theGM(ie, cerebral cortex [type I]). Then,
both the cortex and subcortical WM become involved (type II).
Later, focal contrast enhancement develops at the GM-WM junc-
tion, within the area of T2-weighted or FLAIR hyperintensity
(type III). Enlargement of the contrast-enhancing focus then
evolves into the classic appearance of GB.
Our review of the literature shows that there were 19 cases of
early-stage GBs with MR imaging studies included when they
were published.1-11 With our proposed classification, 2 of 19 le-
sions may be classified as type I2,8; 12, as type II1-3,8-11; and 5, as
type III.4,6-8 Oyama et al8 emphasized the role of DWI in early
tumor detection when they reported a GB that first appeared as
a type I lesion, then transformed to a type II lesion, and finally
transformed to a classic GB before the operation. A type I lesion
reported by Thaler et al2 was described as a “right medial frontal
nondiagnostic T2-weighted hyperintensity.”
It is difficult to study the cell of origin and growth of human
GB because the tumors are typically large and in their late stage
when diagnosed. Therefore, genetically engineeredmousemodels
in which gliomas are induced by manipulation of the mouse ge-
nome at the molecular level are important tools for studying
gliomagenesis.13,14 Using mosaic analysis with a double marker
genetic mouse model, Liu et al15 discovered that an oligodendro-
cyte precursor cell was the cell of origin of malignant gliomas and
FIG 1. A 57-year-old man with a type I lesion. Axial images show a left
parietal cortical lesion, which is hyperintense on the T2-weighted
image (A) and without enhancement on the contrast-enhanced T1-
weighted image (B). T2-weighted (C) and contrast-enhanced T1-
weighted (D) images obtained 7 months later show a left parietal
glioblastoma.
FIG 2. Axial images in a 32-year-old woman with a type II lesion. Left,
T2-weighted image shows hyperintensity involving the left parietal
cortex and subcortical WM. Right, contrast-enhanced T1-weighted
image obtained 4 months later shows a left parietal glioblastoma.
FIG 3. Contrast-enhanced T1-weigthed axial images in a 35-year-old
woman with a type III lesion. Left, a cortical/subcortical contrast-
enhancing lesion is present in the left frontal region. Right, the lesion
transformed to a left frontal glioblastoma after 1 month.
FIG 4. Diagram summarizes themorphologic changes of the 26 early-
stage glioblastomas observed in follow-up MR imaging studies. The
asterisk and dagger indicate the number of lesions transformed from
type I and type II lesions, respectively.
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that the earliest neoplastic lesions were found in the GM. Further-
more, they observed tumor extension in subcortical regions along
WM tracts.15 Another study also found that a glioblastoma could
originate from cortical neurons.16 However, there is always con-
cern about whether results from animal studies can be transferred
to humans. It is not knownwhether gliomas growing inmice with
genetic alterations and different microenvironments resemble
spontaneous human GBs.
In our present study, we found that GM lesions were the ear-
liest MR imaging–detectable abnormalities during human GB
growth. We believe this finding may serve as indirect evidence,
along with that found in themouse gliomamodels,15,16 to suggest
that some GBs may originate from GM. Moreover, the WM
FLAIR/T2-weighted hyperintensity of type II lesions may corre-
spond to GB infiltration rather than just edema. GBs have also
been reported to originate and recur in the subventricular zone,
and it is possible that tumors arising in the cortex are due to
secondary outward migration of abnormal brain tumor cells.17,18
These issues are beyond the scope of this article, and we wish to
only describe and emphasize a subset of GBs that originate in the
cortex and are probably from a different cell origin than periven-
tricular or deep WM GBs.
In the present study, the diagnosis of GB in 16 patients was
confirmed after their MR imaging lesions progressed to classic
ones. Thus, it is possible that those 16 patients initially had low-
grade gliomas, which later transformed to secondary GBs. IDH1
mutation status has recently been considered a molecular marker
of secondaryGBs. The reported IDH1mutation rates for clinically
diagnosed primary and secondary GBs are about 4%–7% and
73%–88%, respectively.19 Among those 16 patients, IDH1muta-
tion status was available in 11 with 2 being positive. Themutation
rate of our patients is lower than expected for secondary GBs. As
reported in previous studies, the median intervals for low-grade
gliomas to transform to GBs ranged from 2.1 to 10.1 years.20 The
MR imaging lesions of those 16 patients progressed to the classic
appearance of GBs in 14 months. Among these, the 2 lesions
with IDH1 mutations progressed to classic GB in 7 and 10
months, respectively. In light of rapid progression to GBs and the
low incidence of IDH1 mutation, we believe the MR imaging le-
sions of those 16 patients were not low-grade gliomas but high-
grade from their origin.
The differential diagnosis for type I lesions should include
postictal change because focal seizures were the clinical presenta-
tion for 3 patients with type I lesions. However, in previous re-
ports, most seizure-induced MR imaging abnormalities were
transient and reversible.21 Permanent structural abnormalities
such as gliosis and focal atrophy are more likely to occur in status
epilepticus.21 In this study, no patients with type I lesions had
status epilepticus, and their abnormalities in the cerebral cortex
persisted even when these lesions transformed to type II or classic
GBs. Moreover, seizure-induced abnormalities tend to involve
both the cortex and subcortical WM and are seldom limited to
GM only.21 Therefore, our type I lesions likely reflect tumor in
GM.
According to the histologic classification of the World Health
Organization, the presence of microvascular proliferation or
pseudopalisading necrosis differentiates GBs from lower-grade
gliomas. These 2 histologic hallmarks are typically present in the
contrast-enhancing component of GB.22,23 Microvascular prolif-
eration is known to result in neovascularity with a disrupted
blood-brain barrier and increased permeability to gadolinium-
based contrast agents and thus contrast enhancement in GB.
Barajas et al22 reported that tissue samples obtained from nonen-
hancing tumor components of GBs demonstrated less microvas-
cular proliferation than those from contrast-enhancing compo-
nents. GBs without contrast enhancement, though relatively rare,
have been reported.23-25 In the study of Utsuki et al,23 purely
non-contrast-enhancing glioblastomas demonstrated only pseu-
dopalisading necrosis and no neovascularity. Although histo-
pathologic diagnosis was only available in 2 type II lesions, we
believe that the other 10 type II lesions were also GBs without
contrast enhancement. The implication of these observationsmay
be that advanced imaging techniques such as perfusion and per-
meabilitymay not reflect the true nature of these small GBs as they
do in larger, classic ones.
The present study helps radiologists be familiar with imaging
findings of early-stageGBs. For a type I or II lesion, early-stageGB
should be included in the differential diagnosis in addition to a
self-limited non-neoplastic lesion. It is challenging to prospec-
tively diagnose early-stage GBs; therefore, aggressive surgical re-
section of these lesions is unlikely. Biopsy may be an alternative
other than short-interval imaging follow-up. Advanced MR im-
aging such as diffusion, perfusion, and MR spectroscopy may
have a role, but further studies are needed.
There are some limitations to our study. First, the diagnosis of
GB was confirmed in only 10 patients who underwent an early
operation. Thus, for the other 16 patients, we can only assume
that their MR imaging lesions were early-stage GBs because they
all eventually developed the typical MR imaging appearance and
histopathology of GBs. Second, because our routine MR imaging
protocol did not include advanced MR imaging techniques such
as diffusion, perfusion, and spectroscopy, we could not assess
their roles in early-stage GBs. Third, the MR imaging findings
describe only macroscopic growth of GBs and not their micro-
scopic changes. Although GBs may arise from GM, their cell of
origin remains unknown. Fourth, tumors included in this study
probably represent only a subset of GBs. GBs arising from the
hippocampus and subventricular zonemay have different growth
patterns on MR imaging. Finally, due to a limited number of
patients and the retrospective nature of our study, we were unable
to determine whether our MR imaging–based classification cor-
relates with outcomes.
CONCLUSIONS
A cortical GM lesion may be the earliest MR imaging–detectable
abnormality in some human GBs. GBs may originate from the
cortical GM and extend into the subcortical WM. Detection of
these lesions while limited to the GM may allow total resection
and potentially improve patient outcome.
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